News

As pharmaceutical manufacturers continue to focus on reliable sourcing of active pharmaceutical ingredients (APIs), quality consistency and supply stability remain important considerations when selecting local anesthetic materials. Ropivacaine Hydrochloride is an important pharmaceutical ingredient used in the development and manufacture of local anesthetic products.

Cosperpharm now offers key intermediates for Upadacitinib, a JAK1-selective inhibitor used in the treatment of rheumatoid arthritis, psoriatic arthritis, and other inflammatory conditions.

Cosperpharm now offers key intermediates for Finerenone, a non-steroidal mineralocorticoid receptor antagonist used in the treatment of chronic kidney disease associated with type 2 diabetes.

Cosperpharm supplies key intermediates for the synthesis of conivaptan hydrochloride, a dual vasopressin V₁ₐ/V₂ receptor antagonist approved for the treatment of euvolemic and hypervolemic hyponatremia. Our portfolio focuses on the two critical building blocks required for the final assembly of the conivaptan molecule.

Cosperpharm supplies a focused portfolio of key intermediates for the synthesis of tolvaptan, an orally active nonpeptide arginine vasopressin V2 receptor antagonist used in the treatment of hyponatremia and autosomal dominant polycystic kidney disease. Our range covers critical building blocks along established synthetic routes, from the core benzazepine scaffold to advanced N-acyl intermediates.

Cosperpharm supplies a focused portfolio of key intermediates for the synthesis of midazolam, a short-acting benzodiazepine used in anesthesia, sedation, and seizure management. Our range covers critical building blocks and advanced intermediates along established synthetic routes.